Prague Med. Rep. 2019, 120, 39-51

https://doi.org/10.14712/23362936.2019.9

Lipoprotein(a) – Link between Atherogenesis and Thrombosis

Danica Labudovic, Irena Kostovska, Katerina Tosheska Trajkovska, Svetlana Cekovska, Julijana Brezovska Kavrakova, Sonja Topuzovska

Department of Medical and Experimental Biochemistry, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, Skopje, North Macedonia

Received April 23, 2019
Accepted September 4, 2019

References

1. Anderson, T. J., Grégoire, J., Pearson, G. J., Barry, A. R., Couture, P., Dawes, M., Francis, G. A., Genest, J. Jr., Grover, S., Gupta, M., Hegele, R. A., Lau, D. C., Leiter, L. A., Lonn, E., Mancini, G. B., McPherson, R., Ngui, D., Poirier, P., Sievenpiper, J. L., Stone, J. A., Thanassoulis, G., Ward, R. (2016) 2016 Canadian Cardiovascular Society Guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can. J. Cardiol. 32(11), 1263–1282. <https://doi.org/10.1016/j.cjca.2016.07.510>
2. Bdeir, K., Cane, W., Canziani, G., Chaiken, I., Weisel, J., Koschinsky, M. L., Lawn, R. M., Bannerman, P. G., Sachais, B. S., Kuo, A., Hancock, M. A., Tomaszewski, J., Raghunath, P. N., Ganz, T., Higazi, A. A., Cines, D. B. (1999) Defensin promotes the binding of lipoprotein(a) to vascular matrix. Blood 94, 2007–2019.
3. Beisiegel, U., Niendorf, A., Wolf, K., Reblin, T., Rath, M. (1990) Lipoprotein(a) in the arterial wall. Eur. Heart J. 11, 174–183. <https://doi.org/10.1093/eurheartj/11.suppl_E.174>
4. Berg, K. (1963) A new serum type system in man: the Lp system. Acta Pathol. Microbiol. Scand. 59, 369–382. <https://doi.org/10.1111/j.1699-0463.1963.tb01808.x>
5. Bergmark, C., Dewan, A., Orsoni, A., Merki, E., Miller, E. R., Shin, M. J., Binder, C. J., Hörkkö, S., Krauss, R. M., Chapman, M. J., Witztum, J. L., Tsimikas, S. (2008) A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J. Lipid Res. 49, 2230–2239. <https://doi.org/10.1194/jlr.M800174-JLR200>
6. Boffa, M. B., Koschinsky, M. L. (2016) Lipoprotein (a): Truly a direct prothrombotic factor in cardiovascular disease? J. Lipid Res. 57, 745–757. <https://doi.org/10.1194/jlr.R060582> <PubMed>
7. Boffa, M. B., Koschinsky, M. L. (2019) Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease. Nat. Rev. Cardiol. 16, 305–318. <https://doi.org/10.1038/s41569-018-0153-2>
8. Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., Reiner, Ž., Riccardi, G., Taskinen, M. R., Tokgozoglu, L., Verschuren, W. M. M., Vlachopoulos, C., Wood, D. A., Zamorano, J. L., Cooney, M. T.; ESC Scientific Document Group (2016) 2016 ESC/EAS Guidelines for the management of dyslipidaemias. Eur. Heart J. 37(39), 2999–3058. <https://doi.org/10.1093/eurheartj/ehw272>
9. Danesh, J., Collins, R., Peto, R. (2000) Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 102(10), 1082–1085. <https://doi.org/10.1161/01.CIR.102.10.1082>
10. Deb, A., Caplice, N. M. (2004) Lipoprotein(a): New insights into mechanisms of atherogenesis and thrombosis. Clin. Cardiol. 27(5), 258–264. <https://doi.org/10.1002/clc.4960270503> <PubMed>
11. de Bruin, T. W., van Barlingen, H., van Linde-Sibenius Trip, M., van Vuurst de Vries, A. R., Akveld, M. J., Erkelens, D. W. (1993) Lipoprotein(a) and apolipoprotein B plasma concentrations in hypothyroid, euthyroid and hyperthyroid subjects. J. Clin. Endocrinol. Metab. 76, 121–126.
12. Dubé, J. B., Boffa, M. B., Hegele, R. A., Koschinsky, M. (2012) Lipoprotein(a): More interesting than ever after 50 years. Curr. Opin. Lipidol. 23, 133–140. <https://doi.org/10.1097/MOL.0b013e32835111d8>
13. Etingin, O. R., Hajjar, D. P., Hajjar, K. A., Harpel, P. C., Nachman, R. L. (1991) Lipoprotein(a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J. Biol. Chem. 266(4), 2459–2465.
14. Frank, S., Durovic, S., Kostner, K., Kostner, G. M. (1995) Inhibitors for the in vitro assembly of Lp(a). Arterioscler. Thromb. Vasc. Biol. 15, 1774–1780. <https://doi.org/10.1161/01.ATV.15.10.1774>
15. Graham, I., Atar, D., Borch-Johnsen, K., Boysen, G., Burell, G., Cifkova, R., Dallongeville, J., De Backer, G., Ebrahim, S., Gjelsvik, B., Herrmann-Lingen, C., Hoes, A., Humphries, S., Knapton, M., Perk, J., Priori, S. G., Pyorala, K., Reiner, Z., Ruilope, L., Sans-Menendez, S., Scholte op Reimer, W., Weissberg, P., Wood, D., Yarnell, J., Zamorano, J. L., Walma, E., Fitzgerald, T., Cooney, M. T., Dudina, A.; European Society of Cardiology (ESC) Committee for Practice Guidelines (CPG) (2007) European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur. Heart J. 28, 2375–2414.
16. Grundy, S. M., Cleeman, J. I., Merz, C. N., Brewer, H. B. Jr., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C. Jr., Stone, N. J.; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler. Thromb. Vasc. Biol. 24, e149–e161.
17. Hermann, W., Biermann, J., Kostner, G. M. (1995) Comparison of effects of N-3 to N-6 fatty acids on serum levels of lipoprotein(a) in patients with coronary artery disease. Am. J. Cardiol. 76, 459–462. <https://doi.org/10.1016/S0002-9149(99)80130-1>
18. Hrzenjak, A., Frank, S., Wo, X., Zhou, Y., Van Berkel, T., Kostner, G. M. (2003) Galactose-specific asialoglycoprotein receptor is involved in lipoprotein (a) catabolism. Biochem. J. 376, 765–771. <https://doi.org/10.1042/bj20030932>
19. Kat, H. (2002) Regulation of functions of vascular wall cells by tissue factor pathway inhibitor: basic and clinical aspects. Arterioscler. Thromb. Vasc. Biol. 22, 539–548. <https://doi.org/10.1161/01.ATV.0000013904.40673.CC>
20. Khan, T. Z., Hsu, L.-Y., Arai, A. E., Rhodes, S., Pottle, A., Wage, R., Gatehouse, P. D., Banya, W., Giri, S., Collins, P., Pennell, D. J., Barbir, M. (2017) Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial. Eur. Heart J. 38, 1561–1569. <https://doi.org/10.1093/eurheartj/ehx178> <PubMed>
21. Klezovitch, O., Edelstein, C., Zhu, L., Scanu, A. M. (1998) Apolipoprotein(a) binds via its C-terminal domain to the protein core of the proteoglycan decorin. Implications for the retention of lipoprotein(a) in atherosclerotic lesions. J. Biol. Chem. 273, 23856–23865. <https://doi.org/10.1074/jbc.273.37.23856>
22. Kojima, S., Harpel, P. C., Rifkin, D. B. (1991) Lipoprotein(a) inhibits the generation of transforming growth factor β: an endogenous inhibitor of smooth muscle cell migration. J. Cell Biol. 113(6), 1439–1445. <https://doi.org/10.1083/jcb.113.6.1439> <PubMed>
23. Kraft, H. G., Lingenhel, A., Raal, F. J., Hohenegger, M., Utermann, G. (2000) Lipoprotein(a) in homozygous familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 20(2), 522–528. <https://doi.org/10.1161/01.ATV.20.2.522>
24. Kronenberg, F., Steinmetz, A., Kostner, G. M., Dieplinger, H. (1996a) Lipoprotein(a) in health and disease. Clin. Lab. Sci. 33, 495–543. <https://doi.org/10.3109/10408369609080056>
25. Kronenberg, F., Utermann, G., Dieplinger, H. (1996b) Lipoprotein(a) in renal disease Am. J. Kidney Dis. 27, 1–25. <https://doi.org/10.1016/S0272-6386(96)90026-8>
26. Linton, M. R. F., Yancey, P. G., Davies, S. S., Jerome, W. G., Linton, E. F., Song, W. L., Doran, A. C., Vickers, K. C. (2000) The Role of Lipids and Lipoproteins in Atherosclerosis. MDText.com, Inc. Available at: https://www.ncbi.nlm.nih.gov/books/NBK343489/.
27. Lippi, G., Targher, G. (2012) Optimal therapy for reduction of lipoprotein(a). J. Clin. Pharm. Ther. 37(1), 1–3. <https://doi.org/10.1111/j.1365-2710.2011.01244.x>
28. Ma, K. L., Gong, T. K., Hu, Z. B., Zhang, Y., Wang, G. H., Liu, L., Chen, P. P., Lu, J., Lu, C. C., Liu, B. C. (2018) Lipoprotein(a) accelerated the progression of atherosclerosis in patients with end-stage renal disease. BMC Nephrol. 19(1), 192. <https://doi.org/10.1186/s12882-018-0986-2> <PubMed>
29. Malgaretti, N. F., Acquati, P. M., Magnaghi, P., Bruno, L., Pontoglio, M., Rocchi, M., Saccone, S., Della Valle, G., D’Urso, M., LePaslier, D. (1992) Characterization by yeast artificial chromosome cloning of the linked apolipoprotein(a) and plasminogen genes and identification of the apolipoprotein(a) 5’ flanking region. Proc. Natl. Acad. Sci. U. S. A. 89(23), 11584–11588. <https://doi.org/10.1073/pnas.89.23.11584> <PubMed>
30. Marcovina, S. M., Lippi, G., Bagatell, C. J., Bremner, W. J. (1996) Testosterone-induced suppression of lipoprotein(a) in normal men: Relation to basal lipoprotein(a) level. Atherosclerosis 122, 89–95. <https://doi.org/10.1016/0021-9150(95)05756-0>
31. McCormick, S. P. A., Schneider, W. J. (2019) Lipoprotein(a) catabolism: a case of multiple receptors. Pathology 51(2), 155–164. <https://doi.org/10.1016/j.pathol.2018.11.003>
32. McLean, J. W., Tomlinson, J. E., Kuang, W. J., Eaton, D. L., Chen, E. Y., Fless, G. M., Scanu, A. M., Lawn, R. M. (1987) cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 330(6144), 132–137. <https://doi.org/10.1038/330132a0>
33. Moriarty, P. M., Hemphill, L. (2016) Lipoprotein apheresis. Endocrinol. Metab. Clin. North Am. 45, 39–54. <https://doi.org/10.1016/j.ecl.2015.09.003>
34. Nordestgaard, B. G., Langsted, A. (2016) A lipoprotein(a) as a cause of cardiovascular disease: Insights from epidemiology, genetics, and biology. J. Lipid Res. 57(11), 1953–1975. <https://doi.org/10.1194/jlr.R071233> <PubMed>
35. Nordestgaard, B. G., Chapman, M. J., Ray, K., Boren, J., Andreotti, F., Watts, G. F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., Lesnik, P., Masana, L., Reiner, Z., Taskinen, M. R., Tokgozoglu, L., Tybjaerg-Hansen, A. (2010) Lipoprotein(a) as a cardiovascular risk factor: current status. Eur. Heart J. 31, 2844–2853. <https://doi.org/10.1093/eurheartj/ehq386> <PubMed>
36. Puckey, L., Knight, B. (1999) Dietary and genetic interactions in the regulation of plasma lipoprotein(a). Curr. Opin. Lipidol. 10, 35–40. <https://doi.org/10.1097/00041433-199902000-00007>
37. Reblin, T., Niemeier, A., Meyer, N., Willnow, T. E., Kronenberg, F., Dieplinger, H., Greten, H., Beisiegel, U. (1997) Cellular uptake of lipoprotein[a] by mouse embryonic fibroblasts via the LDL receptor and the LDL receptor-related protein. J. Lipid Res. 38(10), 2103–2110.
38. Reyes-Soffer, G., Ginsberg, H. N., Ramakrishnan, R. (2017) The metabolism of lipoprotein(a): an everevolving story. J. Lipid Res. 58, 1756–1764. <https://doi.org/10.1194/jlr.R077693> <PubMed>
39. Riches, K., Porter, K. E. (2012) Lipoprotein(a): cellular effects and molecular mechanisms. Cholesterol 2012, 923289. <https://doi.org/10.1155/2012/923289> <PubMed>
40. Riches, K., Franklin, L., Maqbool, A., Peckham, M., Adams, M., Bond, J., Warburton, P., Feric, N. T., Koschinsky, M. L., O’Regan, D. J., Ball, S. G., Turner, N. A., Porter, K. E. (2013) Apolipoprotein(a) acts as a chemorepellent to human vascular smooth muscle cells via integrin αVβ3 and RhoA/ROCK-mediated mechanisms. Int. J. Biochem. Cell Biol. 45, 1776–1783. <https://doi.org/10.1016/j.biocel.2013.05.021> <PubMed>
41. Rifai, N., Ma, J., Sacks, F. M., Ridker, P. M., Hernandez, W. J., Stampfer, M. J., Marcovina, S. M. (2004) Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men. Clin. Chem. 50, 1364–1371. <https://doi.org/10.1373/clinchem.2003.030031>
42. Riis Hansen, P., Kharazmi, A., Jauhiainen, M., Ehnholm, C. (1994) Induction of oxygen free radical generation in human monocytes by lipoprotein(a). Eur. J. Clin. Invest. 24, 497–499.
43. Schmidt, K., Noureen, A., Kronenberg, F., Utermann, G. (2016) Structure, function, and genetics of lipoprotein(a). J. Lipid Res. 57, 1339–1359. <https://doi.org/10.1194/jlr.R067314> <PubMed>
44. Soma, M. R., Osnago-Gadda, I., Paoletti, R., Fumagalli, R., Morrisett, J. D., Meschia, M., Crosignani, P. (1993) The lowering of lipoprotein[a] induced by estrogen plus progesterone replacement therapy in postmenopausal women. Arch. Intern. Med. 153, 1462–1468. <https://doi.org/10.1001/archinte.1993.00410120044006>
45. Sotiriou, S. N., Orlova, V. V., Al-Fakhri, N., Ihanus, E., Economopoulou, M., Isermann, B., Bdeir, K., Nawroth, P. P., Preissner, K. T., Gahmberg, C. G., Koschinsky, M. L., Chavakis, T. (2006) Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin. FASEB J. 20, 559–561. <https://doi.org/10.1096/fj.05-4857fje>
46. Syrovets, T., Thillet, J., Chapman, M. J., Simmet, T. (1997) Lipoprotein(a) is a potent chemoattractant for human peripheral monocytes. Blood 90, 2027–2036.
47. Tholstrup, T., Markmann, P., Vessby, B., Sandstorm, B. (1995) Effects of fats high in individual saturated fatty acids on plasma lipoprotein(a) levels in young health men. J. Lipid Res. 36, 1447–1552.
48. Tsimikas, S. (2017) A test in context: Lipoprotein(a): Diagnosis, prognosis, controversies, and emerging therapies. J. Am. Coll. Cardiol. 69, 692–711. <https://doi.org/10.1016/j.jacc.2016.11.042>
49. Tsironis, L. D., Mitsios, J. V., Milionis, H. J., Elisaf, M., Tselepis, A. D. (2004) Effect of lipoprotein(a) on platelet activation induced by platelet-activating factor: role of apolipoprotein(a) and endogenous PAF-acetylhydrolase. Cardiovasc. Res. 63(1), 130–138. <https://doi.org/10.1016/j.cardiores.2004.03.005>
50. van Capelleveen, J. C., van der Valk, F. M., Stroes, E. G. (2016) Current therapies for lowering lipoprotein(a). J. Lipid Res. 57(9), 1612–1618. <https://doi.org/10.1194/jlr.R053066> <PubMed>
front cover

ISSN 1214-6994 (Print) ISSN 2336-2936 (Online)

Archive